Logo

Immunovia: Patrik Dahlen and Mats Grahn

Aug 26, 2020

Immunovia appointed Patrik Dahlen as its new CEO starting Nov. 1. Dahlen succeeds Mats Grahn, who has been nominated as a member of Immunovia's board.

Dahlen has served as CEO of several diagnostic companies. As CEO of Dako, he implemented a strategic repositioning of the company as a supplier of cancer diagnostics, which resulted in its acquisition by Agilent Technologies for $2.2 billion. As president of life sciences at Perkin Elmer, he was instrumental in building the company's diagnostics business with a niche focus on diagnostic systems for neonatal and prenatal screening.

Breaking News
The Scan

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.

Neurological Outcomes Linked to Innate Immune Features After Cardiac Arrest

Researchers reporting in Med dig into immune features found a few hours after cardiac arrest that correspond with neurological outcomes.

Mouse Study Finds Circadian Rhythm-Related Gene Expression Changes Linked to Sleep Apnea

A paper in PLOS Biology reveals tissue-specific circadian rhythm and gene expression patterns in an intermittent hypoxia-based mouse model of obstructive sleep apnea.

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.